Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases

Wiley Interdisciplinary Reviews: RNA

Volumn 2, Issue 6, 2011, Pages 837-852

  Keeling, Kim M ^a   Bedwell, David M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC G 418; ATALUREN; GENTAMICIN; LIVIDOMYCIN; MEGALIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEGAMYCIN; PAROMOMYCIN; STREPTOMYCIN; TOBRAMYCIN;

CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DRUG BINDING; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SAFETY; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; GENE REPRESSION; GENETIC DISORDER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LOW DRUG DOSE; METHYLMALONIC ACIDEMIA; MOLECULAR RECOGNITION; MUCOPOLYSACCHARIDOSIS; NEPHROTOXICITY; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; OPEN READING FRAME; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; TRANSLATION REGULATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; RNA TRANSLATION; STOP CODON;

MAMMALIA;

AMINOGLYCOSIDES; ANIMALS; CODON, NONSENSE; DRUG DESIGN; GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; NONSENSE MEDIATED MRNA DECAY; PEPTIDE CHAIN TERMINATION, TRANSLATIONAL; RNA, MESSENGER; SUPPRESSION, GENETIC;

EID: 84855342859     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.95     Document Type: Review

References (97)

1. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999, 8:1893-1900.
2. Rodnina MV, Gromadski KB, Kothe U, Wieden HJ. Recognition and selection of tRNA in translation. FEBS Lett 2005, 579:938-942.
3. Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, Philippe M. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 1995, 14:4065-4072.
4. Song H, Mugnier P, Das AK, Webb HM, Evans DR, Tuite MF, Hemmings BA, Barford D. The crystal structure of human eukaryotic release factor eRF1-mechanism of stop codon recognition and peptidyl-tRNA hydrolysis. Cell 2000, 100:311-321.
5. Frolova L, Le Goff X, Zhouravleva G, Davydova E, Philippe M, Kisselev L. Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase. RNA 1996, 2:334-341.
6. Salas-Marco J, Bedwell DM. GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination. Mol Cell Biol 2004, 24:7769-7778.
7. Fearon K, McClendon V, Bonetti B, Bedwell DM. Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem 1994, 269:17802-17808.
8. Cassan M, Rousset JP. UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals. BMC Mol Biol 2001, 2:3.
9. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000, 6:1044-1055.
10. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 1995, 92:5431-5435.
11. Tate WP, Poole ES, Horsfield JA, Mannering SA, Brown CM, Moffat JG, Dalphin ME, McCaughan KK, Major LL, Wilson DN. Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Biochem Cell Biol 1995, 73:1095-1103.
12. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001, 10:291-299.
13. Chernikov VG, Terekhov SM, Krokhina TB, Shishkin SS, Smirnova TD, Kalashnikova EA, Adnoral NV, Rebrov LB, Denisov-Nikol'skii YI, Bykov VA. Comparison of cytotoxicity of aminoglycoside antibiotics using a panel cellular biotest system. Bull Exp Biol Med 2003, 135:103-105.
14. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002, 80:367-376.
15. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 2004, 432:112-118.
16. Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T. The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3′-poly(A) tail of mRNA. Direct association of erf3/GSPT with polyadenylate-binding protein. J Biol Chem 1999, 274:16677-16680.
17. Ivanov PV, Gehring NH, Kunz JB, Hentze MW, Kulozik AE. Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. EMBO J 2008, 27:736-747.
18. Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. PLoS Biol 2008, 6:e111.
19. Atkins JF, Baranov PV, Fayet O, Herr AJ, Howard MT, Ivanov IP, Matsufuji S, Miller WA, Moore B, Prere MF, et al. Overriding standard decoding: implications of recoding for ribosome function and enrichment of gene expression. Cold Spring Harb Symp Quant Biol 2001, 66:217-232.
20. Namy O, Hatin I, Rousset JP. Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep 2001, 2:787-793.
21. Dalphin ME, Stockwell PA, Tate WP, Brown CM. TransTerm, the translational signal database, extended to include full coding sequences and untranslated regions. Nucleic Acids Res 1999, 27:293-294.
22. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, Dietz HC. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002, 295:2258-2261.
23. Kong J, Liebhaber SA. A cell type-restricted mRNA surveillance pathway triggered by ribosome extension into the 3′ untranslated region. Nat Struct Mol Biol 2007, 14:670-676.
24. Tok JB, Bi L. Aminoglycoside and its derivatives as ligands to target the ribosome. Curr Top Med Chem 2003, 3:1001-1019.
25. Recht MI, Douthwaite S, Puglisi JD. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J 1999, 18:3133-3138.
26. Lynch SR, Puglisi JD. Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J Mol Biol 2001, 306:1037-1058.
27. Salas-Marco J, Bedwell DM. Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J Mol Biol 2005, 348:801-815.
28. Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2011, 363:852-863.
29. Keeling KM, Bedwell DM. Recoding therapies for genetic diseases. In: Atkins JF, Gesteland RF, eds. Recoding: Expansion of Decoding Rules Enriches Gene Expression. New York: Springer Publishing; 2010.
30. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008, 24:552-563.
31. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:1683-1692.
32. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, et al. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Respir Cell Mol Biol 2007, 37:57-66.
33. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000, 161(3 Pt 1):860-865.
34. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003, 349:1433-1441.
35. Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003, 27:624-627.
36. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, Comi LI. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003, 22:15-21.
37. James PD, Raut S, Rivard GE, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005, 106:3043-3048.
38. Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 2006, 126:229-231.
39. Martin R. On the relationship between preferred termination codon contexts and nonsense suppression in human cells. Nucleic Acids Res 1994, 22:15-19.
40. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995, 96:1404-1413.
41. Laurent G, Carlier MB, Rollman B, Van Hoof F, Tulkens P. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 1982, 31:3861-3870.
42. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008, 249:91-96.
43. Hobbie SN, Akshay S, Kalapala SK, Bruell CM, Shcherbakov D, Bottger EC. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008, 105:20888-20893.
44. Kawamoto K, Sha SH, Minoda R, Izumikawa M, Kuriyama H, Schacht J, Raphael Y. Antioxidant gene therapy can protect hearing and hair cells from ototoxicity. Mol Ther 2004, 9:173-181.
45. Gilbert DN, Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Finkbeiner HC, Lindsley J, Bennett WM. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis 1989, 159:945-953.
46. Thibault N, Grenier L, Simard M, Bergeron MG, Beauchamp D. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob Agents Chemother 1994, 38:1027-1035.
47. Du M, Keeling KM, Fan L, Liu X, Bedwell DM. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J Biol Chem 2009, 284:6885-6892.
48. Fielding RM, Lewis RO, Moon-McDermott L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm Res 1998, 15:1775-1781.
49. Schiffelers R, Storm G, Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 2001, 48:333-344.
50. Sandoval RM, Reilly JP, Running W, Campos SB, Santos JR, Phillips CL, Molitoris BA. A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy. J Am Soc Nephrol 2006, 17:2697-2705.
51. Ben-Shem A, Jenner L, Yusupova G, Yusupov M. Crystal structure of the eukaryotic ribosome. Science 2010, 330:1203-1209.
52. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, Ben-Yosef T, Baasov T. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett 2006, 16:6310-6315.
53. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, Schacht J, Pilch DS, Ben-Yosef T, Baasov T. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009, 52:2836-2845.
54. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010, 18:3735-3746.
55. Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet 2007, 122:373-381.
56. Brendel C, Belakhov V, Werner H, Wegener E, Gartner J, Nudelman I, Baasov T, Huppke P. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med 2011, 89:389-398.
57. Arakawa M, Shiozuka M, Nakayama Y, Hara T, Hamada M, Kondo S, Ikeda D, Takahashi Y, Sawa R, Nonomura Y, et al. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice (Tokyo). J Biochem 2003, 134:751-758.
58. Schroeder SJ, Blaha G, Moore PB. Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit. Antimicrob Agents Chemother 2007, 51:4462-4465.
59. Uehara Y, Hori M, Umezawa H. Specific inhibition of the termination process of protein synthesis by negamycin. Biochim Biophys Acta 1976, 442:251-262.
60. Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 2009, 206:2285-2297.
61. Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, Gatti RA. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004, 101:15676-15681.
62. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
63. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008, 105:2064-2069.
64. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007, 47:430-444.
65. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
66. Sermet-Gaudelus I, Leal T, DeBoeck K. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. J Cyst Fibros 2008, 7:S22.
67. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatch T, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011.
68. Clancy JP, Konstan MW, Rowe SM. A phase II study of PTC124 in CF patients harboring premature stop mutations. Ped Pulmonol Suppl 2006, 41:A269.
69. Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010, 25:1158-1164.
70. Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 2011, 34:443-447.
71. Dranchak PK, Di Pietro E, Snowden A, Oesch N, Braverman NE, Steinberg SJ, Hacia JG. Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem 2011, 112:1250-1258.
72. Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, Welch EM, Peltz SW, Barton ER, Brown RH Jr, Sweeney HL. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol 2010, 109:901-905.
73. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. PTC124 mediated translational read-through of a nonsense mutation causing usher type 1C. Hum Gene Ther 2011, 22:537-547.
74. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 2009, 106:3585-3590.
75. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, Shen M, Rai G, Battaile KP, Thomas CJ, Simeonov A, et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci USA 2010, 107:4878-4883.
76. Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM. Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci USA 2009, 106:E64.
77. Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, Muhlemann O. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci 2010, 67:677-700.
78. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007, 117:683-692.
79. Maquat LE, Tarn WY, Isken O. The pioneer round of translation: features and functions. Cell 2010, 142:368-374.
80. Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE. NMD: RNA biology meets human genetic medicine. Biochem J 2010, 430:365-377.
81. Lovejoy CA, Cortez D. Common mechanisms of PIKK regulation. DNA Repair (Amst) 2009, 8:1004-1008.
82. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003, 10:207-213.
83. Usuki F, Yamashita A, Higuchi I, Ohnishi T, Shiraishi T, Osame M, Ohno S. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann Neurol 2004, 55:740-744.
84. Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of ullrich disease fibroblasts. Mol Ther 2006, 14:351-360.
85. Abraham RT. The ATM-related kinase, hSMG-1, bridges genome and RNA surveillance pathways. DNA Repair (Amst) 2004, 3:919-925.
86. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, Tazi J, Lejeune F. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol 2007, 178:1145-1160.
87. Gong Q, Stump MR, Zhou Z. Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome. J Mol Cell Cardiol 2011, 50:223-229.
88. McIlwain DR, Pan Q, Reilly PT, Elia AJ, McCracken S, Wakeham AC, Itie-Youten A, Blencowe BJ, Mak TW. Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay. Proc Natl Acad Sci USA 2010, 107:12186-12191.
89. Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, Dietz HC. Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum Mol Genet 2001, 10:99-105.
90. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, Nielsen FC, Jacobsen SE, Nerlov C, Porse BT. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev 2008, 22:1381-1396.
91. Sharifi NA, Dietz HC. Physiologic substrates and functions for mammalian NMD. In: Maquat LE, ed. Nonsense-mediated mRNA Decay. Georgetown, Texas: Landes Bioscience; 2006, 97-109.
92. Seoighe C, Gehring C. Heritability in the efficiency of nonsense-mediated mRNA decay in humans. PLoS One 2010, 5:e11657.
93. Ashton LJ, Brooks DA, McCourt PA, Muller VJ, Clements PR, Hopwood JJ. Immunoquantification and enzyme kinetics of α-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Genet 1992, 50:787-794.
94. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005, 6:489-506.
95. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009, 106:18825-18830.
96. Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 2007, 37:347-356.
97. Mort M, Ivanov D, Cooper DN, Chuzhanova NA. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 2008, 29:1037-1047.